PAVmed (NASDAQ:PAVM – Get Free Report) and Anteris Technologies Global (NASDAQ:AVR – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.
Earnings and Valuation
This table compares PAVmed and Anteris Technologies Global”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PAVmed | $2.99 million | 3.43 | $39.79 million | ($17.12) | -0.61 |
| Anteris Technologies Global | $2.70 million | 87.13 | -$76.29 million | ($1.81) | -3.15 |
Profitability
This table compares PAVmed and Anteris Technologies Global’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PAVmed | 10,672.42% | -754.98% | -19.87% |
| Anteris Technologies Global | -3,944.93% | -252.71% | -169.61% |
Institutional & Insider Ownership
19.9% of PAVmed shares are held by institutional investors. 9.2% of PAVmed shares are held by insiders. Comparatively, 4.5% of Anteris Technologies Global shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
PAVmed has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Anteris Technologies Global has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for PAVmed and Anteris Technologies Global, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PAVmed | 1 | 1 | 1 | 0 | 2.00 |
| Anteris Technologies Global | 1 | 0 | 1 | 0 | 2.00 |
PAVmed currently has a consensus target price of $510.00, suggesting a potential upside of 4,780.38%. Anteris Technologies Global has a consensus target price of $15.00, suggesting a potential upside of 162.70%. Given PAVmed’s higher possible upside, analysts plainly believe PAVmed is more favorable than Anteris Technologies Global.
Summary
PAVmed beats Anteris Technologies Global on 8 of the 12 factors compared between the two stocks.
About PAVmed
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.
